ALT · Altimmune, Inc.
$3.11
+0.16 (+5.42%)
At close · Aug 21
Market Cap
$604.95M
Shares
194.52M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.11
Open$2.98
Day$2.95–3.24
52W close$2.59–6.18
Avg vol 30d4.6M
Short int51.9M · 26.7% float · 11.5d
Short vol23%
Last earningsAug 12, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 12
Up next
Next earnings call
Nov 9, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−16%
below
Price vs 50-day avg
+6%
above
RSI (14)
56
neutral
MACD trend
Positive
52-week position
14%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+12%
trailing
6-month return
−25%
trailing
YTD return
−14%
this year
Relative strength
−37%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+21% holders QoQ · +58 funds added
Insider flow
Accumulating
Net +$44.3K over 90 days · 0% sells
Short interest
Rising
26.70% of float · ▲ +7.7% MoM · 11.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
210 holders — near 3-yr high, broad support
Squeeze score
79
high risk · 0–100
Fundamentals
Revenue growth
+105%
Y/Y
EPS growth
+25%
Y/Y
Free cash flow
$-67.5M
Balance sheet
$9.5M
net cash
Quant / Vol
risk profile
Volatility
69%
annualized · 1-yr
Max drawdown
−58%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−16%
Bearish
Price vs 50-day avg
+6%
Bullish
RSI (14)
56
Neutral
MACD trend
Positive
Bullish
52-week position
14%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+21% holders QoQ · +58 funds added
Insider flow
Accumulating
Net +$44.3K over 90 days · 0% sells
Short interest
Rising
26.70% of float · ▲ +7.7% MoM · 11.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
210 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $3 · 14%
Range high $6
vs 200-day avg -16%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALT
this stock
Altimmune, Inc.
|
$604.95M | -13.9% | +105.0% | — | 26.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALT | +5.8% | +12.3% | -25.2% | +9.5% | -13.9% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +7.2% | +8.6% | -36.8% | +7.0% | -26.1% |
Key facts
CIK
1326190
CUSIP
02155H200
13F (30d)
190 filings
190 filers
Visit website
Investor relations